These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 25574958)

  • 21. Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
    Stürmer M; Staszewski S; Doerr HW
    Antivir Ther; 2007; 12(5):695-703. PubMed ID: 17713153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update.
    Dao H; Mofenson LM; Ekpini R; Gilks CF; Barnhart M; Bolu O; Shaffer N
    Am J Obstet Gynecol; 2007 Sep; 197(3 Suppl):S42-55. PubMed ID: 17825650
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges.
    Kesho Bora Study Group
    Contemp Clin Trials; 2011 Jan; 32(1):74-85. PubMed ID: 20854932
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.
    Galluzzo C; Liotta G; Andreotti M; Luhanga R; Jere H; Mancinelli S; Maulidi M; Sagno JB; Pirillo M; Erba F; Amici R; Ceffa S; Marazzi MC; Vella S; Palombi L; Giuliano M
    J Med Virol; 2012 Oct; 84(10):1553-7. PubMed ID: 22930502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experience with tenofovir disoproxil fumarate for antiretroviral therapy.
    Stephan C
    Expert Opin Pharmacother; 2008 May; 9(7):1197-209. PubMed ID: 18422476
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lustgarten S; Squires KE; Meyer WA; Acosta EP; Schackman BR; Pilcher CD; Murphy RL; Maher WE; Witt MD; Reichman RC; Snyder S; Klingman KL; Kuritzkes DR;
    N Engl J Med; 2004 Apr; 350(18):1850-61. PubMed ID: 15115831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.
    Margot NA; Lu B; Cheng A; Miller MD;
    HIV Med; 2006 Oct; 7(7):442-50. PubMed ID: 16925730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
    Kiage JN; Heimburger DC; Nyirenda CK; Wellons MF; Bagchi S; Chi BH; Koethe JR; Arnett DK; Kabagambe EK
    Lipids Health Dis; 2013 Apr; 12():50. PubMed ID: 23575345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
    ; de Vincenzi I
    Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lower prevalence of drug resistance mutations at first-line virological failure to first-line therapy with atripla vs. tenofovir + emtricitabine/lamivudine + efavirenz administered on a multiple tablet therapy.
    Blanco JL; Montaner JS; Marconi VC; Santoro MM; Campos-Loza AE; Shafer RW; Miller MD; Paredes R; Harrigan R; Nguyen ML; Perno CF; Gonzalez-Hernandez LA; Gatell JM
    AIDS; 2014 Nov; 28(17):2531-9. PubMed ID: 25574957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of 3-drug antiretroviral regimens for the prevention of mother-to-child HIV transmission in Thailand.
    Werayingyong P; Phanuphak N; Chokephaibulkit K; Tantivess S; Kullert N; Tosanguan K; Butchon R; Voramongkol N; Boonsuk S; Pilasant S; Kulpeng W; Teerawattananon Y
    Asia Pac J Public Health; 2015 Mar; 27(2):NP866-76. PubMed ID: 23728769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.
    Shapiro RL; Thior I; Gilbert PB; Lockman S; Wester C; Smeaton LM; Stevens L; Heymann SJ; Ndung'u T; Gaseitsiwe S; Novitsky V; Makhema J; Lagakos S; Essex M
    AIDS; 2006 Jun; 20(9):1281-8. PubMed ID: 16816557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
    Cooper DA; Heera J; Goodrich J; Tawadrous M; Saag M; Dejesus E; Clumeck N; Walmsley S; Ting N; Coakley E; Reeves JD; Reyes-Teran G; Westby M; Van Der Ryst E; Ive P; Mohapi L; Mingrone H; Horban A; Hackman F; Sullivan J; Mayer H
    J Infect Dis; 2010 Mar; 201(6):803-13. PubMed ID: 20151839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial.
    Chi BH; Sinkala M; Mbewe F; Cantrell RA; Kruse G; Chintu N; Aldrovandi GM; Stringer EM; Kankasa C; Safrit JT; Stringer JS
    Lancet; 2007 Nov; 370(9600):1698-705. PubMed ID: 17997151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs.
    Van Laethem K; De Munter P; Schrooten Y; Verbesselt R; Van Ranst M; Van Wijngaerden E; Vandamme AM
    J Clin Virol; 2007 May; 39(1):43-7. PubMed ID: 17369083
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
    Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
    Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
    Moyle G; Higgs C; Teague A; Mandalia S; Nelson M; Johnson M; Fisher M; Gazzard B
    Antivir Ther; 2006; 11(1):73-8. PubMed ID: 16518962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
    Crespo M; Ribera E; Suárez-Lozano I; Domingo P; Pedrol E; López-Aldeguer J; Muñoz A; Viladés C; Sánchez T; Viciana P; Teira R; García-Alcalde ML; Vergara A; Lozano F; Galindo MJ; Cosin J; Roca B; Terrón A; Geijo P; Vidal F; Garrido M;
    J Antimicrob Chemother; 2009 Jan; 63(1):189-96. PubMed ID: 18988678
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
    Girard PM; Cabié A; Michelet C; Verdon R; Katlama C; Mercié P; Morand-Joubert L; Pétour P; Monchecourt F; Chêne G; Trylesinski A;
    J Antimicrob Chemother; 2009 Jul; 64(1):126-34. PubMed ID: 19403652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.